Larry Yan
0009-0006-2343-898X
Mirati Therapeutics (United States)
1 paper found
Refreshing results…
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Missing publications? Search for publications with a matching author name.